Research programme: indomethacin/phosphatidylcholine - PLx Pharma/UTHealth

Drug Profile

Research programme: indomethacin/phosphatidylcholine - PLx Pharma/UTHealth

Alternative Names: Phosphatidylcholine-enriched indomethacin

Latest Information Update: 02 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PLx Pharma; University of Texas Health Science Center at Houston
  • Class Nonsteroidal anti-inflammatories; Phospholipids
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase Unknown Congenital heart defects

Most Recent Events

  • 30 Mar 2012 Investigation in Congenital heart disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top